Jun 2026 (Q2 FY26) — Jul 29, 2026
Ionis Q2 FY26 — Strong Commercial Momentum and Pipeline Progress Despite Eplontersen Setback
Read the full callIonis (IONS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Ionis earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 268 | −40.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -38.2 | −69.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -115 | −192.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$44.12 +3.33% · +$1.42
Performance −38.2% 1Y
1Y: $71.37 on 14 Oct 2025 → $44.12. High $86.5 (6 Feb 2026), low $42.38 (13 Oct 2026).
- Previous close
- $42.7
- 52-week range
- $42.38 – $86.5
- One year
- −39.05%
Overview
- Symbol
- IONS
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — Apr 29, 2026
Ionis Q1 FY26 — Strong Commercial Momentum and Raised Full-Year Guidance
Read the full callDec 2025 (Q4 FY25) — Feb 25, 2026
Ionis Q4 FY25 — Strong Commercial Launches & Pipeline Progress
Read the full callEvery analysed call
Ionis earnings calls (IONS)
Financials
What the filings say
Net profit, year on year: −193% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 134 | 227 | 132 | 452 | 157 | 203 | 246 | 268 |
| Expenses | 282 | 337 | 278 | 312 | 317 | 418 | 364 | 370 |
| Operating profit | -149 | -111 | -147 | 140 | -160 | -214 | -117 | -102 |
| Operating margin | −111.1% | −48.9% | −111.6% | 30.9% | −102.2% | −105.5% | −47.7% | −38.2% |
| Interest | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
| Profit before tax | -144 | -107 | -147 | 124 | -128 | -228 | -92 | -113 |
| Tax rate | 2.5% | 2.5% | −0.1% | −0.0% | −0.2% | −0.7% | −0.2% | −1.1% |
| Net profit | -140 | -104 | -147 | 124 | -129 | -229 | -93 | -115 |
| EPS ($ per share) | -0.95 | -0.66 | -0.93 | 0.78 | -0.80 | -1.41 | -0.56 | -0.69 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -967 | -708 | -1,131 | -1,160 | -1,430 | -1,796 | -2,250 | -2,631 |
| Total liabilities | 1,481 | 1,549 | 1,646 | 1,840 | 1,961 | 2,603 | 2,415 | 3,035 |
| Fixed assets | 132 | 154 | 181 | 178 | 74 | 71 | 94 | 123 |
| Investments | — | — | — | 1,246 | 1,710 | 1,932 | 2,056 | 2,305 |
| Total assets | 2,668 | 3,233 | 2,390 | 2,612 | 2,534 | 2,990 | 3,004 | 3,524 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 603 | 346 | 36 | 31 | -274 | -308 | -501 | -269 |
| Cash from investing | -930 | -41 | 274 | 195 | -263 | -214 | -134 | -278 |
| Cash from financing | 476 | 100 | -597 | 246 | -55 | 644 | 478 | 676 |
| Net cash flow | 149 | 404 | -286 | 472 | -593 | 123 | -157 | 130 |
| Capital expenditure | -14 | -31 | -35 | -12 | -16 | -24 | -45 | -51 |
| Free cash flow | 589 | 315 | 1 | 19 | -290 | -331 | -546 | -320 |
IONS revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Ionis Operations | — | — | 100% | 100% | 100% | 100% | 100% | 100% | -40.7% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
236 filings between Oct 16, 2025 and Aug 31, 2026.
Open market
decisions to buy or sellPurchases
$1.06M
2 purchases by 1 insider
Sales
$127.06M
121 sales by 19 insiders
78% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 8
- Award — granted as compensation
- 94
- Option exercise — converted options into shares
Also filed: 11 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Monia Brett P | — | $30.32M | Jun 26, 2026 |
| HOUGEN ELIZABETH L | — | $17.87M | Mar 17, 2026 |
| BENNETT C FRANK | — | $9.65M | Jul 7, 2026 |
| Geary Richard S | — | $9.45M | Nov 6, 2025 |
| Devers Shannon L. | — | $8.22M | Apr 2, 2026 |
| LOSCALZO JOSEPH | — | $7.09M | May 4, 2026 |
| KLEIN JOSEPH III | — | $6.00M | Jul 1, 2026 |
| Swayze Eric | — | $5.24M | Jun 25, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | BENNETT C FRANK EVP, Chief Scientific Officer | Other | 110 | $5.6K |
| Aug 31, 2026 | Birchler Brian EVP, Corp and Development Ops | Other | 58 | $3.0K |
| Aug 31, 2026 | Monia Brett P Chief Executive Officer | Other | 98 | $5.0K |
| Aug 31, 2026 | O'NEIL PATRICK R. EVP CLO & General Counsel | Other | 63 | $3.2K |
| Jul 31, 2026 | Hayden Michael R Director | Purchase | 5,000 | $258.0K |
| Jul 30, 2026 | Hayden Michael R Director | Purchase | 15,000 | $800.7K |
| Jul 15, 2026 | HERMAN JOAN E Director | Option exercise | 5,220 | $0 |
| Jul 15, 2026 | BERTHELSEN SPENCER R Director | Option exercise | 5,220 | $0 |
| Jul 7, 2026 | Diaz Allene M. Director | Option exercise 10b5-1 plan | 10,111 | $476.3K |
| Jul 7, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Sale 10b5-1 plan | 362 | $30.5K |
| Jul 7, 2026 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale 10b5-1 plan | 15,000 | $1.28M |
| Jul 7, 2026 | BENNETT C FRANK EVP, Chief Scientific Officer | Other 10b5-1 plan | 15,000 | $0 |
| Jul 7, 2026 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale 10b5-1 plan | 5,536 | $462.7K |
| Jul 7, 2026 | Diaz Allene M. Director | Sale 10b5-1 plan | 10,111 | $863.6K |
| Jul 1, 2026 | KLEIN JOSEPH III Director | Sale 10b5-1 plan | 99 | $7.9K |
| Jul 1, 2026 | KLEIN JOSEPH III Director | Option exercise 10b5-1 plan | 11,518 | $460.0K |
| Jul 1, 2026 | KLEIN JOSEPH III Director | Sale 10b5-1 plan | 11,419 | $902.6K |
| Jun 26, 2026 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Option exercise 10b5-1 plan | 26,000 | $1.58M |
| Jun 26, 2026 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Sale 10b5-1 plan | 26,000 | $2.11M |
| Jun 26, 2026 | O'NEIL PATRICK R. EVP CLO & General Counsel | Sale 10b5-1 plan | 3,069 | $245.5K |
| Jun 26, 2026 | Baroldi Joseph EVP, Chief Business Officer | Sale 10b5-1 plan | 5,635 | $451.7K |
| Jun 26, 2026 | Baroldi Joseph EVP, Chief Business Officer | Option exercise 10b5-1 plan | 1,769 | $57.7K |
| Jun 26, 2026 | Baroldi Joseph EVP, Chief Business Officer | Option exercise 10b5-1 plan | 3,866 | $219.5K |
| Jun 26, 2026 | Monia Brett P Chief Executive Officer | Sale 10b5-1 plan | 50,000 | $4.03M |
| Jun 26, 2026 | Monia Brett P Chief Executive Officer | Option exercise 10b5-1 plan | 50,000 | $2.84M |
| Jun 25, 2026 | Monia Brett P Chief Executive Officer | Sale 10b5-1 plan | 21,072 | $1.65M |
| Jun 25, 2026 | Monia Brett P Chief Executive Officer | Option exercise 10b5-1 plan | 21,072 | $686.9K |
| Jun 25, 2026 | Swayze Eric EVP Research | Sale 10b5-1 plan | 10,602 | $839.5K |
| Jun 24, 2026 | Monia Brett P Chief Executive Officer | Option exercise 10b5-1 plan | 14,565 | $474.8K |
| Jun 24, 2026 | Monia Brett P Chief Executive Officer | Sale 10b5-1 plan | 14,565 | $1.14M |
| Jun 15, 2026 | BERTHELSEN SPENCER R Director | Sale 10b5-1 plan | 8,000 | $587.9K |
| Jun 15, 2026 | BERTHELSEN SPENCER R Director | Option exercise 10b5-1 plan | 8,000 | $195.4K |
| Jun 12, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Option exercise 10b5-1 plan | 12,000 | $391.2K |
| Jun 12, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Option exercise 10b5-1 plan | 21,000 | $1.28M |
| Jun 12, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Option exercise 10b5-1 plan | 7,951 | $484.1K |
| Jun 12, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Option exercise 10b5-1 plan | 19,895 | $1.13M |
| Jun 12, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Sale 10b5-1 plan | 19,842 | $1.47M |
| Jun 12, 2026 | Kordasiewicz Holly B. EVP, Chief Development Officer | Sale 10b5-1 plan | 41,004 | $3.00M |
| Jun 1, 2026 | BERTHELSEN SPENCER R Director | Sale 10b5-1 plan | 8,000 | $605.4K |
| Jun 1, 2026 | BERTHELSEN SPENCER R Director | Option exercise 10b5-1 plan | 8,000 | $195.4K |
| May 14, 2026 | Monia Brett P Chief Executive Officer | Sale 10b5-1 plan | 3,220 | $253.3K |
| May 14, 2026 | Monia Brett P Chief Executive Officer | Option exercise 10b5-1 plan | 3,220 | $105.0K |
| May 13, 2026 | Monia Brett P Chief Executive Officer | Sale 10b5-1 plan | 1,316 | $102.7K |
| May 13, 2026 | Monia Brett P Chief Executive Officer | Option exercise 10b5-1 plan | 1,316 | $42.9K |
| May 4, 2026 | LOSCALZO JOSEPH Director | Sale 10b5-1 plan | 17,781 | $1.34M |
| May 4, 2026 | LOSCALZO JOSEPH Director | Option exercise 10b5-1 plan | 10,968 | $417.4K |
| May 4, 2026 | LOSCALZO JOSEPH Director | Sale 10b5-1 plan | 59,508 | $4.46M |
| May 4, 2026 | LOSCALZO JOSEPH Director | Option exercise 10b5-1 plan | 16,000 | $1.04M |
| May 4, 2026 | LOSCALZO JOSEPH Director | Option exercise 10b5-1 plan | 12,000 | $722.4K |
| May 4, 2026 | LOSCALZO JOSEPH Director | Option exercise 10b5-1 plan | 16,000 | $686.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for IONIS PHARMACEUTICALS INC
Free account. Everything above stays public.
Write why you follow IONIS PHARMACEUTICALS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading